- Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has anno...
Pioneering solution provides scientists with actionable answers faster to accelerate scientific discovery CAS, a division of the American Chemical Soci...
-FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, today announced the U.S. launch of the FDR ...
AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, highlights the value of its HUB partn...
Apellis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first tre...
POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and the Coalition for Epidemic Preparedness Innovatio...
Engagement with FDA on GH001 IND complete response ongoing The fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months...
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, announces service and infrastructure ...
Cytiva, a Danaher company and a leader in the life sciences industry, is expanding its ÄKTA portfolio with the addition of a system designed to opti...
HMNC Brain Health (“HMNC”), a global precision psychiatry biopharmaceutical company, in collaboration with Spruce Biosciences, Inc. (OTCQB: S...
Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next...
Everlab, the AI-powered health platform reimagining preventive care, announced a US$10 million (AU$15 million) seed round led by global growth equity fir...
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US Cornerstone of investment is...
© 2025 Biopharma Boardroom. All Rights Reserved.
